Navigation Links
Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022 - Immunotherapy Represents a Paradigm Shift in Cancer Therapy Along Multiple Fronts - Research and Markets
Date:3/22/2017

DUBLIN, Mar 22, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022" drug pipelines to their offering.

Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022 report gives comprehensive insight on clinical and non-clinical aspects involved in the development and integration of immune check point inhibitors as main streamline drugs in the immunotherapy treatment. Report helps to identify the basic classification and molecular mechanism of action of immune check point inhibitors drugs available in the market and in the clinical pipeline.  Currently there are 4 Immune Check Point Inhibitors drugs commercially available in the market and more than 70 drugs in clinical pipeline.

Immunotherapy represents a paradigm shift in cancer therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing anti-tumor immunity.

The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab were approved by FDA and are indicated for the treatment of squamous non-small cell lung cancer and metastatic melanoma, respectively. Several other anti PD-1 drugs are in late stage clinical trials and are expected to achieve the regulatory approval in the near future. Moreover, the anti PD-L1, antibody which targets the tumor cells rather than the T cells is also being studied and tested.

Immune checkpoint inhibitors appears to offer an advantage compared with standard cytotoxic chemotherapy and produces high response rates, durable response and the survival curves which indicate the sustained remission of long therapy which has been completed. Safety with the new therapies is of concern since the immune system is being suppressed by the cancer and the immune checkpoint inhibitors are turning the suppressed immune system.

Companies Mentioned

  • Advaxis
  • Agenus
  • Amgen
  • Bristol Myers Squibb
  • Faron Pharmaceuticals
  • Genentech
  • Genocea
  • Incyte Corporation
  • Innate Pharma
  • Kite Pharma
  • MacroGenics
  • Merck
  • NewLink Genetics Corp
  • Sorrento Therapeutics
  • TG Therapeutics

Key Topics Covered:

1. Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy

2. Major Immune Checkpoints Proteins

3. Mechanism of Action of Immune Checkpoint Inhibitors

4. CTLA 4 Inhibition Approved Drugs to Target Immune Checkpoints

5. PD-1 & PD-L1 Inhibition Approved Drugs to Target Immune Checkpoints

6. Biomarkers Associated with Immune Checkpoint Inhibitors

7. Combination Approaches with Immune Checkpoint Inhibitors

8. Global Immune Checkpoint Inhibitors Market

9. Global Immune Checkpoint Inhibitors Clinical Pipeline

10. Global Immune Checkpoint Inhibitors Market Dynamics

11. Future Potential of Immune Checkpoint Inhibitors

12. PDL1-Protein-Inhibitors Clinical Pipeline by Company, Indication  & Phase

13. Marketed PDL1-Protein-Inhibitors Clinical Insight by Company & Phase

14. CTLA-4-Inhibitors Clinical Pipeline by Company, Indication & Phase

15. Marketed CTLA-4-Inhibitors Clinical Insight by Company, Phase & Indication

16. PD-1-Protein-Inhibitors Clinical Pipeline by Company, Phase & Indication

17. Marketed PD-1-Protein-Inhibitors Clinical Insight by Company & Phase

18. Competitive Landscape

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/jkc62j/global_immune

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-immune-check-point-inhibitors-market--clinical-pipeline-insight-2022---immunotherapy-represents-a-paradigm-shift-in-cancer-therapy-along-multiple-fronts---research-and-markets-300427893.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... and PETACH TIKVAH, Israel , Aug. ... a leading developer of adult stem cell technologies for ... ending June 30, 2017. ... for our pivotal Phase 3 trial to investigate NurOwn ... President and Chief Executive Officer of BrainStorm. "We have ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
(Date:8/4/2017)... Aug. 4, 2017 The search for test ... a physician/patient consult has long been the goal of ... notable focus of the largest meeting of lab professionals ... healthcare market research firm Kalorama Information.  The firm said ... offerings or related supplies and software were at the ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... 17, 2017 , ... The award-winning producers of the Innovations ... Council for Therapeutic Recreation Certification (NCTRC), slated to air nationwide, fourth quarter 2017. ... a non-profit, international organization dedicated to professional excellence for the protection of consumers ...
(Date:8/17/2017)... ... ... Georgia Urology, the largest urology practice in the Southeastern United ... in East Cobb (4800 Olde Towne Parkway, Suite 220, Marietta). , “Georgia ... Haber, Georgia Urology’s managing partner. “She brings a passionate, fresh perspective on general urology ...
(Date:8/17/2017)... ... 17, 2017 , ... The 2017 Integrated Delivery Network (IDN) ... interact with their GPO and supplier partners. This year, Winifred Hayes, RN, PhD, ... of Clinical Value Analytics, have been invited to present “Episode-based Reimbursement and the ...
(Date:8/17/2017)... ... ... In its just released 2018 Edition, The Best Lawyers in America named ... consecutive year that Hardiman and Mills have been honored and the seventh year in ... Care Law while Mills was recognized in the Administrative and Regulatory Law category. ...
(Date:8/17/2017)... Angeles, California (PRWEB) , ... August 17, 2017 , ... ... the number of South Korean men obtaining plastic surgery, largely influenced by the growing ... and beauty clinic Beverly Hills Physicians notes that standards of male appearance are changing ...
Breaking Medicine News(10 mins):